• HyperPFU™ high-fidelity DNA polymerase Guide

  2026-08-21

  HyperPFU high-fidelity DNA polymerase is intended for accurate PCR amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It produces blunt-ended amplicons, so it should not be selected when the workflow directly requires 3′-A overhangs or preformed sticky ends.

• WP1066: JAK2/STAT3 Inhibitor Workflows

  2026-08-20

  WP1066 supports mechanism-driven studies in cancer cells, AML models, and macrophage-centered regeneration assays. This practical guide connects pathway pharmacology with dose design, orthogonal readouts, and troubleshooting for more reproducible experiments.

• Polymyxin B: Designing Better Infection Assays

  2026-08-20

  Polymyxin B sulfate is more than a bactericidal reagent: its membrane activity and immune-cell effects can shape experimental readouts. This guide explains how to use it in Gram-negative infection research while separating antimicrobial action from host and microbiome biology.

• SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis

  2026-08-19

  The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced renal fibrosis and inflammation. Using AZ505 and LLY507 in a cisplatin-induced chronic kidney disease model, together with tubular epithelial cell experiments, the authors connect SMYD2 inhibition with reduced epithelial–mesenchymal transition, inflammatory cytokine expression, and Smad3/STAT3 signaling.

• SB 202190 and the ECM Invasion Axis

  2026-08-19

  A translational perspective on how SB 202190, a selective p38 MAP kinase inhibitor, can help researchers interrogate ECM internalisation, cancer cell invasion, inflammation, and apoptosis while maintaining rigorous mechanistic controls.

• (S)-Mephenytoin for CYP2C19 Organoids

  2026-08-18

  Use (S)-Mephenytoin as a quantitative CYP2C19 substrate to connect intestinal organoid biology with oxidative drug metabolism. This workflow emphasizes matrix controls, concentration bracketing, metabolite-resolved analysis, and troubleshooting for more interpretable pharmacokinetic studies.

• HNRNPU K181 Lactylation Rewires Cervical Cancer

  2026-08-18

  This Advanced Science study identifies HNRNPU lysine 181 lactylation as a metabolic signaling mechanism that stabilizes PHGDH transcripts and increases serine biosynthesis in cervical cancer. Its integrated computational, molecular, cellular, and in vivo evidence connects lactate accumulation with post-transcriptional control of tumor metabolism and suggests a pharmacologically tractable regulatory axis.

• H-Aggregated IR-1061 for NIR-II Cancer Therapy

  2026-08-17

  Yu et al. developed RR9-coated anionic liposomes that deliver IR-1061 and carboplatin while transferring the dye’s H-aggregated state to αvβ3-overexpressing tumor cell membranes. This design couples NIR-II fluorescence imaging with membrane-localized photothermal therapy and temperature-sensitive chemotherapy, providing a mechanistic framework for integrated cancer theranostics.

• Reactive Oxygen Species Assay Kit for OA Research

  2026-08-17

  Translate superoxide biology into actionable live-cell measurements with a DHE workflow tailored to chondrocytes, explants, and oxidative-stress models. This guide connects the APExBIO assay format with the PQQ–Nrf2–IGF1R findings in age-related osteoarthritis while emphasizing controls, normalization, and DHE-specific troubleshooting.

• Partial BACE Inhibition and Synaptic Transmission

  2026-08-16

  Satir et al. showed that moderate β-secretase inhibition can reduce amyloid β secretion by up to approximately 50% without disrupting synaptic transmission in cultured rat cortical neurons. The study supports a dose-sensitive prevention strategy in which BACE exposure is sufficient to limit amyloid β production but remains below levels associated with neuronal functional impairment.

• Regorafenib Suppresses Melanoma via RRM2

  2026-08-15

  A 2024 iScience study identifies RRM2 as a downstream mediator of Regorafenib activity in melanoma and connects its reduction with ERK/E2F3 pathway inhibition, apoptosis, and impaired malignant behavior. The work provides a mechanistic framework for studying Regorafenib in melanoma models while distinguishing pathway-level evidence from clinical treatment conclusions.

• SCH772984 for Reliable ERK1/2 Assays

  2026-08-14

  This scenario-driven guide explains how SCH772984 (SKU A3805) can improve the interpretation and reproducibility of ERK-dependent cell viability, proliferation, and cytotoxicity assays. It covers selectivity, dosing logic, DMSO stock preparation, pathway biomarkers, cross-domain radiosensitivity questions, and practical product-selection criteria.

• Fingolimod (FTY720) for Immune-Cell Workflows

  2026-08-14

  Fingolimod (FTY720) gives researchers a controllable way to study S1P-dependent lymphocyte trafficking, CNS signaling, and dose-related tumor-cell responses. This guide translates those mechanisms into practical assays and places them alongside, but not in place of, magnetic CAR-T-mimicking strategies for solid tumors.

• α-Amanitin Workflows for RNA Polymerase II Studies

  2026-08-13

  Use α-Amanitin as a controlled transcriptional perturbagen for RNA polymerase function assays, nascent RNA measurements, and developmental models. The most reliable workflows pair its rapid RNA polymerase II inhibition with viability, timing, and stage-matched controls that separate direct transcription effects from secondary cytotoxicity.

• Oleanolic Acid: Liposome Assay Workflows

  2026-08-13

  Build reproducible Oleanolic acid liposome studies around its lipophilic chemistry, inducible nitric oxide synthase induction, and immune-pathway readouts. A nanoparticle exclusion chromatography workflow adds a practical advantage by measuring free and encapsulated hydrophilic and lipophilic cargos in the same dual-loaded formulation.

14951 records 1/997 page Next 12345 下5页 Last page